These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2095 related articles for article (PubMed ID: 20647199)

  • 1. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
    Stone JH; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Turkiewicz A; Tchao NK; Webber L; Ding L; Sejismundo LP; Mieras K; Weitzenkamp D; Ikle D; Seyfert-Margolis V; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh KA; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Specks U;
    N Engl J Med; 2010 Jul; 363(3):221-32. PubMed ID: 20647199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
    Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
    N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
    Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.
    Langford CA
    Clin Exp Immunol; 2011 May; 164 Suppl 1(Suppl 1):31-4. PubMed ID: 21447129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
    Keogh KA; Ytterberg SR; Fervenza FC; Carlson KA; Schroeder DR; Specks U
    Am J Respir Crit Care Med; 2006 Jan; 173(2):180-7. PubMed ID: 16224107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties.
    Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
    Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
    PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.
    Puéchal X; Iudici M; Perrodeau E; Bonnotte B; Lifermann F; Le Gallou T; Karras A; Blanchard-Delaunay C; Quéméneur T; Aouba A; Aumaître O; Cottin V; Hamidou M; Ruivard M; Cohen P; Mouthon L; Guillevin L; Ravaud P; Porcher R; Terrier B;
    JAMA Netw Open; 2022 Nov; 5(11):e2243799. PubMed ID: 36441554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
    Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avacopan for the Treatment of ANCA-Associated Vasculitis.
    Jayne DRW; Merkel PA; Schall TJ; Bekker P;
    N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
    Santana AN; Woronik V; Halpern AS; Barbas CS
    J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 105.